Autologous T Cells

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
86 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
T Cell
Trial Type
Treatment
Last Update
13 hours ago
SparkCures ID
2085
NCT Identifier
NCT06904066

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.